Laryngeal Cancer Therapeutics Market Report 2025

This report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.

The laryngeal cancer therapeutics market size has grown strongly in recent years. It will grow from $3.06 billion in 2024 to $3.27 billion in 2025 at a compound annual growth rate (CAGR) of 6.7%. The growth in the historic period can be attributed to increasing incidence of laryngeal cancer, evolution of treatment modalities, clinical trial activities, government initiatives and funding, patient awareness and education.

The laryngeal cancer therapeutics market size is expected to see strong growth in the next few years. It will grow to $4.15 billion in 2029 at a compound annual growth rate (CAGR) of 6.2%. The growth in the forecast period can be attributed to targeted and immunotherapy advances, genomic medicine integration, rising geriatric population, global health collaborations, expanded role of telemedicine. Major trends in the forecast period include advancements in medical research, immunotherapy advancements, personalized medicine and biomarkers, combination therapies, patient-centric care, healthcare policy and access.

The rising prevalence of tobacco is projected to drive the growth of the laryngeal cancer therapeutics market in the future. Tobacco refers to the leaves of plants from the genus Nicotiana, which are harvested and processed for various uses, including smoking, chewing, and snuffing. Tobacco consumption is a significant risk factor for laryngeal cancer and significantly influences both the disease's development and treatment outcomes. Laryngeal cancer therapeutics focus on addressing the effects of tobacco use on the disease and its management. For instance, in October 2024, the 2024 National Youth Tobacco Survey published by the US Food and Drug Administration (USFDA), a federal agency in the United States, reported that 1.1% of all students (approximately 2.25 million) currently use tobacco products, with 10.1% of high school students (about 1.58 million) and 5.4% of middle school students (around 640,000) using tobacco. Additionally, 2.8% of students (about 760,000) reported current use of any combustible tobacco product, while 3% (approximately 840,000) indicated using multiple tobacco products. Therefore, the increasing prevalence of tobacco is driving the growth of the laryngeal cancer therapeutics market.

The rising demand for chemotherapy is expected to stimulate growth in the laryngeal cancer therapeutics market moving forward. Chemotherapy is a medical treatment that utilizes drugs or medications to treat and manage various types of cancer. It plays a crucial role in the management of advanced-stage laryngeal cancer by preserving parts of the larynx, controlling the growth of cancer cells, alleviating symptoms, and enhancing the patient’s quality of life. For example, in January 2022, the American Cancer Society, a US-based voluntary health organization, estimated that there were 18,060,100 cancer survivors in the United States in 2022. Moreover, in June 2022, data from Macmillan Cancer Support, a UK-based cancer charity, indicated that the number of people living with cancer reached 3 million in 2022 and is expected to rise to nearly 3.5 million by 2025 and 4 million by 2030 in the UK. Consequently, the growing demand for chemotherapy is driving the growth of the laryngeal cancer therapeutics market.

Prominent companies in the laryngeal cancer treatment market are focusing on developing innovative technologies such as Zeno AI to expand their customer base, drive sales, and increase revenue. Zeno AI represents a real-time AI solution designed for cancer detection and classification in the Ear, Nose, and Throat (ENT) region. For example, WSK Medical B.V., a Netherlands-based AI software company, introduced Zeno AI in September 2022. This real-time AI solution facilitates early detection of throat cancer during endoscopic examinations, providing instant localization and classification of laryngeal lesions on endoscopic videos. Zeno AI aims to streamline the early detection and diagnosis of laryngeal cancer, reducing analysis time and enabling faster implementation of care plans.

In May 2024, Moffitt Cancer Center, a cancer treatment and research center based in the US, announced a collaboration with Fulgent Pharma. The goal of this partnership is to enhance cancer treatment through clinical development and pre-clinical co-development initiatives, merging Moffitt's clinical expertise with Fulgent's nanotherapeutics and genomics platforms to expedite personalized cancer therapies. Fulgent Pharma is a US-based innovative company that focuses on cancer therapeutics, specializing in nanoencapsulation technology and personalized oncology treatments.

Major companies operating in the laryngeal cancer therapeutics market report are Pfizer Inc., F. Hoffmann La Roche Ltd., Merck & Co., AbbVie Inc., Novartis AG, Bayer AG, Sanofi-Aventis LLC, Bristol Myers Squibb, AstraZeneca PLC, Abbott Laboratories, GlaxoSmithKline PLC, Eli Lilly and Company, Amgen Inc., C.H. Boehringer Sohn AG & Co. KG., Regeneron Pharmaceuticals Inc., Incyte Corporation, Aurobindo Pharma Ltd., Cipla Inc., Hikma Pharmaceuticals PLC, Amneal Pharmaceuticals LLC, Lupin Limited, Seagen Inc., Exelixis Pharmaceuticals Inc., BeiGene Ltd., Taiho Pharmaceutical Co. Ltd., Genentech Inc., Mirati Therapeutics Inc.

North America was the largest region in the laryngeal cancer therapeutics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the laryngeal cancer therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the laryngeal cancer therapeutics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The laryngeal cancer therapeutics market consists of revenues earned by entities by providing services such as diagnostic services, treatment planning and coordination, surgical interventions, radiation therapy, and chemotherapy administration. The market value includes the value of related goods sold by the service provider or included within the service offering. The laryngeal cancer therapeutics market includes sales of radiation therapy machines, targeted therapies, immunotherapy drugs, surgical instruments, and voice prostheses. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

Laryngeal cancer therapeutics encompass various treatments and therapeutic approaches employed to manage laryngeal cancer, a type of cancer that originates in the tissues of the larynx (voice box). The selection of treatment modalities is influenced by factors such as the stage and location of the cancer, overall health, and individual preferences.

The primary treatment types for laryngeal cancer therapeutics include chemotherapy, immunotherapy, and others. Chemotherapy involves the use of potent drugs to kill or inhibit the growth of rapidly dividing cells, including cancer cells. In the context of laryngeal cancer, chemotherapy is often utilized to shrink cancerous cells before surgical intervention. The administration routes for chemotherapy drugs include oral and parenteral, and these drugs are distributed through hospital pharmacies, online pharmacies, and retail pharmacies. End users of laryngeal cancer therapeutics include hospitals, homecare, specialty centers, and others.

The laryngeal cancer therapeutics market research report is one of a series of new reports that provides laryngeal cancer therapeutics market statistics, including laryngeal cancer therapeutics industry global market size, regional shares, competitors with a laryngeal cancer therapeutics market share, detailed laryngeal cancer therapeutics market segments, market trends and opportunities, and any further data you may need to thrive in the laryngeal cancer therapeutics industry. This laryngeal cancer therapeutics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.